LYCOS RETRIEVER 
Cytogen Corporation
built 201 days ago
Cytogen Corporation is a biopharmaceutical company in Princeton, NJ, whose mission is to set new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company's cancer management franchise currently comprises four FDA-approved products: ProstaScint, used to image the extent and spread of prostate cancer; BrachySeed implants for prostate cancer therapy; OncoScint CR/OV, a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet, for the relief of cancer-related bone pain. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. Cytogen and its joint venture partner, Progenics Pharmaceuticals, are developing in vivo immunotherapies for prostate cancer based on PSMA. The Company ... has U.S. marketing rights to the late-stage product candidate Combidex(r), a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases.
Source:
Founded in 1980, Cytogen Corporation of Princeton, NJ, is a biopharmaceutical company that acquires, develops and commercializes innovative molecules targeting the sites and stages of cancer progression. Cytogen's marketed products include QUADRAMET® (samarium Sm-153 lexidronam injection) and PROSTASCINT® (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide in the United States. Cytogen ... has exclusive United States marketing rights to COMBIDEX® (ferumoxtran-10) for all applications, and the exclusive right to market and sell ferumoxytol (previously Code 7228) for oncology applications in the United States. Cytogen's development pipeline consists of therapeutics targeting prostate-specific membrane antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells and the neovasculature of solid tumors. Full prescribing information for the Company's products is available at www.cytogen.com or by calling 800-833-3533. For more information, please visit the Company's website at www.cytogen.com, which is not part of this press release.
Source:
Cytogen Corporation has a product portfolio that’s tightly focused on oncology. Quadramet© is a targeted palliative therapy for painful bone metastases. Stringent regulatory requirements and physicians’ reluctance to prescribe a myelosuppressive agent to patients with compromised bone marrow combined to severely limit Quadramet© prescriptions.
Source:
Cytogen Corporation announced updated data from a Phase 1 dose escalation study evaluating QUADRAMET (samarium Sm-153 lexidronam injection) in combination with bortezomib (Velcade, Millennium Pharmaceuticals, Inc.) in patients with relapsed multiple myeloma. Results from this study demonstrated that the combination was tolerable and of 32 evaluable patients, 15 participants, or more than 46% achieved a response or stabilization of their disease. Of these, six patients responded to the combination regimen, with three achieving a complete response (CR) and three achieving a minor response (MR). Of the 15 patients who achieved either a response to treatment or stabilization of their disease, nine had previously failed treatment with bortezomib. There were two parallel arms to the study. The first arm administered bortezomib at 1.0 mg/m(2) and the second arm administered bortezomib at 1.3 mg/m(2).
Source:
PRINCETON, N.J., Oct. 26 /PRNewswire-FirstCall/ -- Cytogen Corporation (Nasdaq: CYTO) today announced the appointment of Kevin Bratton as the Company's new chief financial officer. A finance executive with more than 35 years of experience in healthcare, biotechnology and technology, Mr. Bratton was previously chief financial officer at Metrologic Instruments, Inc. (Nasdaq: MTLG), a global technology company. During his tenure at Metrologic, Mr. Bratton directed the company's finance operations during a period of significant growth in sales, net income, cash flow from operations, and working capital.
Source:
Cytogen Corporation and Dowpharma today announced a collaboration to create a targeted oncology product designed to treat prostate and other cancers. Under the agreement, Dowpharma's proprietary MeO-DOTA bifunctional chelant technology will be used to radiolabel Cytogen's prostate-specific membrane antigen (PSMA) antibody with a therapeutic radionuclide. PSMA is a protein highly expressed on the surface of prostate cancer cells and the neovasculature of many solid tumors.
Source:
MORE ABOUT
Cytogen Corporation